As It Prepares for a Future with Wyeth, Pfizer Reports Ho-Hum Q1 Results
This article was originally published in The Pink Sheet Daily
Executive Summary
Pfizer’s first-quarter results were down, but in line with the company’s and Wall Street’s expectations.
You may also be interested in...
Pfizer’s Business Units Enable It To Be Nimble Even as It Grows
Wyeth integration is on track, with closing expected end of Q3 or Q4; anti-trust review is in early stages, with concern primarily about animal health overlap.
HBV Approval Gives Viread A Needed Boost
U.S. clearance follows nod from European regulators.
HBV Approval Gives Viread A Needed Boost
U.S. clearance follows nod from European regulators.